Vectibix panitumumab: Interim Phase IIIb data

Interim 12-week data from the open-label, U.S. Phase IIIb PACCE trial in 500 evaluable patients showed that

Read the full 174 word article

How to gain access

Continue reading with a
two-week free trial.